Alumis Inc
NASDAQ:ALMS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alumis Inc
NASDAQ:ALMS
|
US |
|
GRN Holding Corp
OTC:GRNF
|
US |
|
MFA Financial Inc
NYSE:MFA
|
US |
|
R
|
Ral Yatirim Holding AS
IST:RALYH.E
|
TR |
|
Allied Minds PLC
LSE:ALM
|
UK |
|
Interroll Holding AG
SIX:INRN
|
CH |
|
Volkswagen AG
F:VOWB
|
DE |
|
Cobalt Blue Holdings Ltd
ASX:COB
|
AU |
|
H
|
Hor Kew Corporation Ltd
SGX:BBP
|
SG |
|
STMicroelectronics NV
OTC:STMEF
|
CH |
|
E
|
Eprcomunicazione SpA Societa Benefit
MIL:EPRB
|
IT |
|
New Peoples Bankshares Inc
OTC:NWPP
|
US |
|
E-L Financial Corp Ltd
TSX:ELF
|
CA |
|
Murphy Oil Corp
NYSE:MUR
|
US |
|
Brundage-Bone Concrete Pumping Holdings Inc
NASDAQ:BBCP
|
US |
|
Orion Oyj
OTC:ORINF
|
FI |
Alumis Inc
Alumis Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in South San Francisco, California and currently employs 128 full-time employees. The company went IPO on 2024-06-28. Alumis Inc. is a clinical-stage biopharmaceutical company. The company develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. The company builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. The company has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Alumis Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in South San Francisco, California and currently employs 128 full-time employees. The company went IPO on 2024-06-28. Alumis Inc. is a clinical-stage biopharmaceutical company. The company develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. The company builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. The company has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
